Figure 2.
Pooled risk ratio of focal segmental glomerulosclerosis recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.